The incidence of invasive fungal infections in China is increasing year by year.However,due to relevant policies,hospitals face restrictions on the variety of antifungal drugs they can procure.Currently,the pharmacological effects of the clinically used antifungal drugs are highly similar,which may lead to delays in the treatment of invasive fungal infections.The authors summarized the indications and clinical application status of antifungal drugs in China,and through an analysis of drug accessibility,understood the pharmacological characteristics of common antifungal drugs and the limitations of some irreplaceable drugs.Based on this,it is believed that relevant authorities should appropriately relax the policy restrictions on the variety of antifungal drugs.Medical institutions should periodically(every 1 to 2 years)adjust and optimize their supply catalogs and variety structures.Meanwhile,due to the low recommended status of itraconazole in recent domestic and international guidelines and expert consensus on deep fungal diseases,but its relatively high recommended status in superficial fungal infection guidelines,such as skin and mucous membranes infections,it is suggested that the selection of whether to introduce an antimicrobial drug list should be based on the distribution characteristic of fungal diseases in medical institutions.
维普
万方数据